The aim of this systematic review and meta‐analysis was to assess the risk of acute pancreatitis and pancreatic cancer among patients taking glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs). This evidence concerns the gene GCG and pancreatic neoplasm.